New drug Q702 aims to boost immune system against blood cancers
NCT ID NCT06712810
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This early-phase trial is testing a new drug called Q702 in about 46 people with various blood cancers or histiocytic disorders (diseases where certain immune cells grow out of control). Q702 is designed to help the immune system kill cancer cells and help the bone marrow make normal blood cells. The main goals are to find a safe dose and see if the drug can shrink tumors or control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Q702 (a drug that helps the immune system kill cancer cells and supports normal blood cell production)
What this could lead to
If it works, this could point toward a new treatment option for people with certain blood cancers or histiocytic disorders who have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 46 participants, so the main goal is safety and dosing—not yet proving effectiveness. It may not work for many patients, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.